ToxSci Advance Access originally published online on August 19, 2004
Toxicological Sciences 2004 82(1):341-358; doi:10.1093/toxsci/kfh254
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Toxicological Sciences vol. 82 no. 1 © Society of Toxicology 2004; all rights reserved.
Modulation of Notch Processing by 
-Secretase Inhibitors Causes Intestinal Goblet Cell Metaplasia and Induction of Genes Known to Specify Gut Secretory Lineage Differentiation
* Safety Assessment US, AstraZeneca Pharmaceuticals, Wilmington, Delaware, 19850; DMPK, AstraZeneca Pharmaceuticals, Wilmington, Delaware, 19850; Neuroscience, AstraZeneca Pharmaceuticals, Wilmington, Delaware, 19850; Target Biology, AstraZeneca Pharmaceuticals, Wilmington, Delaware, 19850; ||| Chemistry, AstraZeneca Pharmaceuticals, Wilmington, Delaware, 19850; and || Safety Assessment UK, AstraZeneca Pharmaceuticals, Alderley Park, Macclesfield, Cheshire SK10 4TG, United Kingdom
Received May 26, 2004; accepted August 11, 2004
It is anticipated that 
-secretase inhibitors (-Sec-I) that modulate Notch processing will alter differentiation in tissues whose architecture is governed by Notch signaling. To explore this hypothesis, Han Wistar rats were dosed for up to 5 days with 10–100 µmol/kg b.i.d. -Sec-I from three chemical series that inhibit Notch processing in vitro at various potencies (Notch IC50). These included an arylsulfonamide (AS) (142 nM), a dibenzazepine (DBZ) (1.7 nM), and a benzodiazepine (BZ) (2.2 nM). The DBZ and BZ caused dose-dependent intestinal goblet cell metaplasia. In contrast, the AS produced no detectable in vivo toxicity, despite higher exposure to free drug. In a time course using BZ, small intestinal crypt cell and large intestinal glandular cell epithelial apoptosis was observed on days 1–5, followed by goblet cell metaplasia on days 2–5 and crypt epithelial and glandular epithelial regenerative hyperplasia on days 4–5. Gene expression profiling of duodenal samples from BZ-dosed animals revealed significant time-dependent deregulation of mRNAs for various panendocrine, hormonal, and transcription factor genes. Somatostatin, secretin, mucin, CCK, and gastrin mRNAs were elevated twofold or more by day 2, and a number of candidate ‘early-predictive’ genes were altered on days 1–2, remaining changed for 4–5 days; these included Delta1, NeuroD, Hes1-regulated adipsin, and the Hes-regulated transcriptional activator of gut secretory lineage differentiation, the rat homolog of Drosophila atonal, Rath1. Western blotting of fecal protein from BZ-and DBZ-dosed animals exhibited increased levels of both anti-Rath1 reactive protein and anti-adipsin reactive proteins, confirming their potential value as noninvasive biomarkers of intestinal goblet metaplasia.
Key Words: -secretase; Notch receptor; Notch intracellular domain; NICD; intestinal goblet metaplasia; Rath1; Hes1; adipsin; atonal.
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  G. van Tetering, P. van Diest, I. Verlaan, E. van der Wall, R. Kopan, and M. Vooijs Metalloprotease ADAM10 Is Required for Notch1 Site 2 Cleavage J. Biol. Chem., November 6, 2009; 284(45): 31018 - 31027. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. J. Finch, L. Soucek, M. R. Junttila, L. B. Swigart, and G. I. Evan Acute Overexpression of Myc in Intestinal Epithelium Recapitulates Some but Not All the Changes Elicited by Wnt/{beta}-Catenin Pathway Activation Mol. Cell. Biol., October 1, 2009; 29(19): 5306 - 5315. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. Cullion, K. M. Draheim, N. Hermance, J. Tammam, V. M. Sharma, C. Ware, G. Nikov, V. Krishnamoorthy, P. K. Majumder, and M. A. Kelliher Targeting the Notch1 and mTOR pathways in a mouse T-ALL model Blood, June 11, 2009; 113(24): 6172 - 6181. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. S. Guseh, S. A. Bores, B. Z. Stanger, Q. Zhou, W. J. Anderson, D. A. Melton, and J. Rajagopal Notch signaling promotes airway mucous metaplasia and inhibits alveolar development Development, May 15, 2009; 136(10): 1751 - 1759. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
V. Asnafi, A. Buzyn, S. Le Noir, F. Baleydier, A. Simon, K. Beldjord, O. Reman, F. Witz, T. Fagot, E. Tavernier, et al. NOTCH1/FBXW7 mutation identifies a large subgroup with favorable outcome in adult T-cell acute lymphoblastic leukemia (T-ALL): a Group for Research on Adult Acute Lymphoblastic Leukemia (GRAALL) study Blood, April 23, 2009; 113(17): 3918 - 3924. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. Okamoto, K. Tsuchiya, Y. Nemoto, J. Akiyama, T. Nakamura, T. Kanai, and M. Watanabe Requirement of Notch activation during regeneration of the intestinal epithelia Am J Physiol Gastrointest Liver Physiol, January 1, 2009; 296(1): G23 - G35. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. M. Ghaleb, G. Aggarwal, A. B. Bialkowska, M. O. Nandan, and V. W. Yang Notch Inhibits Expression of the Kruppel-Like Factor 4 Tumor Suppressor in the Intestinal Epithelium Mol. Cancer Res., December 1, 2008; 6(12): 1920 - 1927. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. Spilman, P. Lessard, M. Sattavat, C. Bush, T. Tousseyn, E. J. Huang, K. Giles, T. Golde, P. Das, A. Fauq, et al. A {gamma}-secretase inhibitor and quinacrine reduce prions and prevent dendritic degeneration in murine brains PNAS, July 29, 2008; 105(30): 10595 - 10600. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. Zhao, M. Yu, M. Neitzel, J. Marugg, J. Jagodzinski, M. Lee, K. Hu, D. Schenk, T. Yednock, and G. Basi Identification of {gamma}-Secretase Inhibitor Potency Determinants on Presenilin J. Biol. Chem., February 1, 2008; 283(5): 2927 - 2938. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Yan and G. D. Plowman Delta-like 4/Notch Signaling and Its Therapeutic Implications Clin. Cancer Res., December 15, 2007; 13(24): 7243 - 7246. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. H. Choi and E. Norstrom Moderate Reduction of {gamma}-Secretase: Is There a Therapeutic Sweet Spot? J. Neurosci., December 12, 2007; 27(50): 13579 - 13580. [Full Text] [PDF]
|
|
|
|
 |
|
 B. P. Imbimbo, E. Del Giudice, D. Colavito, A. D'Arrigo, M. D. Carbonare, G. Villetti, F. Facchinetti, R. Volta, V. Pietrini, M. F. Baroc, et al. 1-(3',4'-Dichloro-2-fluoro[1,1'-biphenyl]-4-yl)-cyclopropanecarboxylic Acid (CHF5074), a Novel {gamma}-Secretase Modulator, Reduces Brain beta-Amyloid Pathology in a Transgenic Mouse Model of Alzheimer's Disease without Causing Peripheral Toxicity J. Pharmacol. Exp. Ther., December 1, 2007; 323(3): 822 - 830. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Z. Ren, D. Schenk, G. S. Basi, and I. P. Shapiro Amyloid -Protein Precursor Juxtamembrane Domain Regulates Specificity of {gamma}-Secretase-dependent Cleavages J. Biol. Chem., November 30, 2007; 282(48): 35350 - 35360. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Li, H. Wen, C. Brayton, F. M. Laird, G. Ma, S. Peng, L. Placanica, T. C. Wu, B. J. Crain, D. L. Price, et al. Moderate Reduction of {gamma}-Secretase Attenuates Amyloid Burden and Limits Mechanism-Based Liabilities J. Neurosci., October 3, 2007; 27(40): 10849 - 10859. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 X. Li, B. B. Madison, W. Zacharias, A. Kolterud, D. States, and D. L. Gumucio Deconvoluting the intestine: molecular evidence for a major role of the mesenchyme in the modulation of signaling cross talk Physiol Genomics, May 11, 2007; 29(3): 290 - 301. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. D. Best, D. W. Smith, M. A. Reilly, R. O'Donnell, H. D. Lewis, S. Ellis, N. Wilkie, T. W. Rosahl, P. A. Laroque, C. Boussiquet-Leroux, et al. The Novel {gamma} Secretase Inhibitor N-[cis-4-[(4-Chlorophenyl)sulfonyl]-4-(2,5-difluorophenyl)cyclohexyl]-1,1,1-trifluoromethanesulfonamide (MRK-560) Reduces Amyloid Plaque Deposition without Evidence of Notch-Related Pathology in the Tg2576 Mouse J. Pharmacol. Exp. Ther., February 1, 2007; 320(2): 552 - 558. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. A. Hyde, N. A. McHugh, J. Chen, Q. Zhang, D. Manfra, A. A. Nomeir, H. Josien, T. Bara, J. W. Clader, L. Zhang, et al. Studies to Investigate the in Vivo Therapeutic Window of the {gamma}-Secretase Inhibitor N2-[(2S)-2-(3,5-Difluorophenyl)-2-hydroxyethanoyl]-N1-[(7S)-5-methyl-6-oxo-6,7-dihydro-5H-dibenzo[b,d]azepin-7-yl]-L-alaninamide (LY411,575) in the CRND8 Mouse J. Pharmacol. Exp. Ther., December 1, 2006; 319(3): 1133 - 1143. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. E. Clarke, I. Churcher, S. Ellis, J. D. J. Wrigley, H. D. Lewis, T. Harrison, M. S. Shearman, and D. Beher Intra- or Intercomplex Binding to the {gamma}-Secretase Enzyme: A MODEL TO DIFFERENTIATE INHIBITOR CLASSES J. Biol. Chem., October 20, 2006; 281(42): 31279 - 31289. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. C. Fraering, W. Ye, M. J. LaVoie, B. L. Ostaszewski, D. J. Selkoe, and M. S. Wolfe {gamma}-Secretase Substrate Selectivity Can Be Modulated Directly via Interaction with a Nucleotide-binding Site J. Biol. Chem., December 23, 2005; 280(51): 41987 - 41996. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Bjerknes and H. Cheng Gastrointestinal Stem Cells. II. Intestinal stem cells Am J Physiol Gastrointest Liver Physiol, September 1, 2005; 289(3): G381 - G387. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. Z. Stanger, R. Datar, L. C. Murtaugh, and D. A. Melton Direct regulation of intestinal fate by Notch PNAS, August 30, 2005; 102(35): 12443 - 12448. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 V. Zecchini, R. Domaschenz, D. Winton, and P. Jones Notch signaling regulates the differentiation of post-mitotic intestinal epithelial cells Genes & Dev., July 15, 2005; 19(14): 1686 - 1691. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 F. Radtke and H. Clevers Self-Renewal and Cancer of the Gut: Two Sides of a Coin Science, March 25, 2005; 307(5717): 1904 - 1909. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Crosnier, N. Vargesson, S. Gschmeissner, L. Ariza-McNaughton, A. Morrison, and J. Lewis Delta-Notch signalling controls commitment to a secretory fate in the zebrafish intestine Development, March 1, 2005; 132(5): 1093 - 1104. [Abstract] [Full Text] [PDF]
|
|